Ensysce Biosciences (ENSC) Non-Current Debt (2019 - 2025)

Ensysce Biosciences (ENSC) has reported Non-Current Debt for 7 consecutive years, with $306708.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non-Current Debt rose 1.67% year-over-year to $306708.0 in Q4 2025; TTM through Dec 2025 was $306708.0, a 1.67% increase from a year earlier, with the FY2025 full-year figure at $306708.0, up 1.67% from the prior year.
• Non-Current Debt was $306708.0 for Q4 2025 at Ensysce Biosciences, down from $387702.0 in the prior quarter.
• Over five years, Non-Current Debt peaked at $17.2 million in Q4 2021 and troughed at $245973.0 in Q1 2024.
• A 5-year average of $2.8 million and a median of $450100.5 in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 767.37% in 2021 and tumbled 96.07% in 2023, its largest moves.
• Over 5 years, Non-Current Debt stood at $17.2 million in 2021, then sank by 74.36% to $4.4 million in 2022, then sank by 80.6% to $854697.0 in 2023, then plunged by 64.71% to $301660.0 in 2024, then gained by 1.67% to $306708.0 in 2025.
• The last three Non-Current Debt figures came in at $306708.0 (Q4 2025), $387702.0 (Q3 2025), and $424521.0 (Q2 2025), per Business Quant data.